Feasibility of Novel Diagnostics for TB
in Endemic Countries
Analytic core lab rutgers
Moldova
peru
Mission
To support the evaluation of early-stage TB diagnostics & novel diagnostic strategies in the context of existing clinical algorithms in TB endemic countries.
FEND for TB will perform proof-of-principle studies of novel diagnostics & strategies and provide feedback to diagnostic developers on the performance of the technologies and their most effective use in endemic settings.
About
The primary purpose of the FEND for TB Consortium is to evaluate early stage diagnostics and novel diagnostic strategies for tuberculosis in the context of existing clinical algorithms in TB endemic countries.
fendtech@njms.rutgers.edu
Collaborators
Protocols
The Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) Consortium, funded by the U.S. National Institutes of Health, is comprised of a group of international clinical and laboratory investigators with the primary purpose of supporting the evaluation of early-stage tuberculosis diagnostic assays and strategies in the context of existing clinical algorithms in tuberculosis endemic countries.
Samples
FEND-TB 2 is collecting prospective samples from adult index TB cases in Peru and from drug-resistant index cases in Moldova. In addition, a large repository of samples from FEND-TB 1 is available, which includes adult, pediatric, and drug-resistant cases.
Prospective Sample Collection
Peru
Drug Resistant Protocol
Moldova
Repository Samples Available
Peru, South Africa, Uganda, Vietnam
Pediatric Protocol
Peru, Uganda
Drug Resistant Protocol
Moldova, South Africa, Vietnam
For Manufacturers
FEND mission is to support the evaluation of early-stage TB diagnostics & novel diagnostic strategies in the context of existing clinical algorithms in TB endemic countries.
FEND for TB will perform proof-of-principle studies of novel diagnostics & strategies and provide feedback to diagnostic developers on the performance of the technologies and their most effective use in endemic settings.
Applications for TB diagnostics are now being accepted from August 30 to November 30, 2025. Applications may be reviewed on a rolling basis.
Support
Research on this website (FEND-TB.org) was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number U01AI152084. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.